DATA - The Buzz Show: Geron Corporation (NASDAQ: GERN) IMbark Phase 2 Data: Journal of Clinical Oncology

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Geron Corporation Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology”

Geron Corporation (NASDAQ: GERN) surged over 16% in premarket trading after the company announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology.

The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as the evidence of disease-modifying activity from biomarker and bone marrow fibrosis assessments and the results reinforce imetelstat’s novel approach to the treatment of myelofibrosis.

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

For more information, please visit: Geron Corporation

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Geron Corporation (NASDAQ: GERN) IMbark Phase 2 Data: Journal of Clinical Oncology first appeared on Financial Buzz .

For further details see: